Latest in Cardiology from ACC.org

• TAVI PCI, ACASA-TAVI, TRIC-I-HF: New Answers in Structural Heart Care
  Three late-breaking trials presented at ESC Congress 2026 offer new insights into the management of structural heart disease and heart failure (HF), spanning coronary revascularization during TAVI, transcatheter treatment of tricuspid regurgitation, and post-TAVI antithrombotic therapy. Together, the TAVI PCI, ACASA-TAVI and TRIC-I-HF studies provide important evidence to help refine treatment strategies and improve patient […]
• NOTION-4: Short-Term DOAC Therapy and Subclinical Leaflet Thickening Post TAVR
  A three-month direct oral anticoagulant (DOAC) regimen shortly after successful TAVR substantially reduced hypoattenuated leaflet thickening (HALT) during treatment vs. single antiplatelet therapy (SAPT) alone, based on findings from the NOTION-4 trial presented at ESC Congress 2026 and simultaneously published in JACC. However, researchers noted that this effect was diminished around nine months following discontinuation […]
• TIME-HF: Nurse-Led, Mobile Health-Supported Collaborative Care Model Improves HF Outcomes in India
  A nurse-led collaborative care model that integrated mobile health improved overall survival and days out of the hospital among patients with heart failure with reduced ejection fraction (HFrEF) in India, based on findings from the TIME-HF trial presented at ESC Congress 2026 and simultaneously published in Circulation. Researchers highlight that this model may serve as […]
• LUMINARA: Oral Relaxin Receptor Agonist AZD5462 in Treating Chronic HF
  The addition of AZD5462, an oral once-daily relaxin family peptide receptor 1 agonist, was well tolerated among individuals with well-treated chronic heart failure (HF), based on findings from LUMINARA presented at ESC Congress 2026 and simultaneously published in Circulation. In addition, researchers observed encouraging effects on cardiovascular hemodynamic measures across a wide range of left […]
• PADN-HF-PH: Pulmonary-Artery Denervation For Pulmonary Hypertension Associated With Left Heart Disease and HF
  Pulmonary-artery denervation, in addition to guideline-directed medical therapy, resulted in fewer events of clinical worsening than medical therapy alone in patients with pulmonary hypertension associated with left heart disease and heart failure (HF), based on findings from the PADN-HF-PH trial presented at ESC Congress 2026 and simultaneously published in NEJM.